Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500443 | 0.97 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL4508376 | 0.89 | SIGMAR1 (0.75) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL466854 | 0.87 | SIGMAR1 (0.71) | SIGMAR1KCNH2 | |
| SCHEMBL4521954 | 0.86 | SIGMAR1 (0.80) | SIGMAR1KCNH2 | |
| SCHEMBL8234157 | 0.83 | SIGMAR1 (0.75) | SIGMAR1KCNH2 | |
| SCHEMBL4560092 | 0.82 | SIGMAR1 (0.78) | SIGMAR1KCNH2 | |
| SCHEMBL12187054 | 0.82 | SIGMAR1 (0.76) | SIGMAR1KCNH2 | |
| SCHEMBL8234160 | 0.81 | SIGMAR1 (0.71) | SIGMAR1KCNH2 | |
| SCHEMBL9974264 | 0.81 | SIGMAR1 (0.77) | SIGMAR1KCNH2 | |
| SCHEMBL467006 | 0.80 | SIGMAR1 (1.00) | SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232093-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-13 | — | — | US | claimed |
| US-8202872-B2 | Pyrazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-19 | — | — | US | claimed |
| US-20090264442-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVES, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-1994032-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-11-26 | — | — | EP | claimed |
| WO-2007098953-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-07 | — | — | WO | claimed |
| US-20120232093-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-13 | — | — | US | disclosed |
| US-8202872-B2 | Pyrazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-19 | — | — | US | disclosed |
| US-20090264442-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVES, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264442-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885KCNH2 1469/4885 |
| US-20120232093-A1 | PYRAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885KCNH2 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.